Company intelligence / Profile preview
Arovella Therapeutics
Preston, Victoria, Australiaarovella.com ↗
- Ownership
- Private
- Employees
- ~27
- Development stage
- Other
01
Overview
Arovella is developing CAR-iNKT cell therapies, with ALA-101 targeting CD19+ blood cancers and ALA-105 targeting CLDN18.2 in solid tumors. The company has enhanced its solid tumor pipeline with novel armouring technology.
- Therapeutic areas
- OncologyHematology
- Modalities
- CAR-iNKT cell therapy
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Sparx GroupUniversity of North Carolina Lineberger Comprehensive Cancer Center
Beyond the preview
Go deeper on Arovella Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arovella Therapeutics.